Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × tislelizumab × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Stomach Neoplasms 3 Nasopharyngeal Carcinoma 3 Esophageal Squamous Cell Carcinoma 3 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Non Squamous Non-small Cell Lung Cancer 1 Neoplasm Recurrence, Local 1 Motor Activity 1 Lung Neoplasms 1 Gastric Cancer Stage 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 B-cell Malignancies 1 Advanced Squamous Non Small Cell Lung Cancer 1 Advanced Non-squamous Non-small-cell Lung Cancer 1 Advanced Malignancies 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03924986 2025-01-31

RATIONALE-309

BeiGene

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡